a multicentre, open-label, randomised, controlled, superiority trial

This dataset originates from the RESPONS trial. The objective of the trial was to establish the immunogenicity in HBV non-responders of a three-dose revaccination series at a 4 week interval with Twinrix (GlaxoSmithKline), Fendrix (GlaxoSmithKline), or HBVaxPro-40 (Merck Sharp & Dohme) compared with a standard revaccination series of three Engerix-B (with 20 μg HBsAg) or HBVaxPro-10 (with 10 μg HBsAg). In this revaccination trial, after enrolment, we collected data about age, sex, body-mass index, smoking habits, country of birth, general information on medical conditions, and primary vaccination schedule. Furthermore, data for timing between vaccinations and the interval between last vaccination and post-vaccination antibody concentrations were collected. These data were provided by participating centres originating from their medical records. Important notice: 56 participants did not provide further consent for the reuse of data in future studies. Therefore in this dataset the data of 56 participants is not shown